Professor Chris Jones, DCMO, told the Inquiry: "The Welsh Government allocated additional resources to health boards for the new antiviral medications in 2015/16. Funding was allocated in line with anticipated health board treatment demand and there was no cap put on the number of patients that could be treated within any health board."